Harmony Biosciences Holdings, Inc. (HRMY)

29,32 +0,39 (+1,35%) Börsenschluss: 04:00PM EDT

Harmony Biosciences Holdings, Inc.

630 West Germantown Pike
Suite 215
Plymouth Meeting, PA 19462
United States
484 539 9800
https://www.harmonybiosciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 246

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Jeffrey S. Aronin	Founder & Non-Executive Chairman	185,67k	N/A	1968
Dr. Jeffrey M. Dayno M.D.	President, CEO & Director	1,26M	N/A	1957
Mr. Jeffrey Dierks M.B.A.	Executive VP & Chief Commercial Officer	830,75k	N/A	1972
Mr. Andrew Serafin J.D., M.B.A.	Executive VP & Chief Strategy Officer	647,42k	N/A	1975
Dr. Kumar Budur M.D., M.S.	Executive VP & Chief Medical Officer	760,81k	N/A	N/A
Mr. David Bradshaw	Head of Technical Operations	N/A	N/A	N/A
Luis Sanay	Head of Investor Relations	N/A	N/A	N/A
Mr. Christian Ulrich	General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Tricia Glover	Chief Compliance Officer	N/A	N/A	N/A
Ms. Audrey Murphy SPHR	Vice Presidet of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Corporate Governance

Harmony Biosciences Holdings, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 10, Shareholderrechte: 8, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.